Introduction
Although intensive research focused on improving innate immunity to eradicate malignant cells, primary cancer treatment relied for decades almost exclusively on surgery, chemotherapy and radiation therapy. Only with monoclonal antibodies and stem cell transplantation, immunotherapy has become a clinical option for the treatment of cancer. Recently, agents that modulate the immune system to induce or enhance anti-tumor responses have markedly moved immunotherapy forward. Particularly, checkpoint inhibition (CKi) and adoptive T cell therapy have generated great enthusiasm. CKi includes monoclonal antibodies against the cytotoxic T lymphocyte associated protein 4 (CTLA-4), the programed cell death protein 1 (PD-1) or the programed cell death ligand 1 (PD-1 L). 1 Adoptive T cell therapy, in turn, redirects T cells to tumor antigens and comprises tumorinfiltrating lymphocytes (TILs), T cell receptor (TCR) engineered T cells and chimeric antigen receptor (CAR) genetransduced T cells. Application of TILs is limited since they have generated encouraging results in only a minority of cancers 2 and TCR T cell application is restricted to Human Leukocyte Antigen (HLA)-expressing antigens. 3 In contrast, CAR T cells act in an HLA-independent manner and have the potential to effectively recognize sufficiently expressed target surface antigens. Recently, the Oncologic Drug Advisory Committee of the Federal Drug Administration (FDA) unanimously recommended the approval of CAR T cell therapy in the USA for the treatment of acute lymphoblastic leukemia (ALL) patients.
CAR-expressing T cell. T cells are genetically engineered to express CARs via viral (retroviral, lentiviral, adenoviral) or non-viral (electroporation, transposon-based or gene-editing systems) vectors. CARs expressed on T cells combine antigen-binding properties of an antibody with the activating, effector and long-term function of a T cell. In contrast to monoclonal antibodies, CAR T cells do not depend on additional players of the immune system to destroy the target cell and are not compromised by short in vivo persistence.
Depending on the composition of the intracellular domain, different CAR generations can be distinguished ( Fig.  1 ): First-generation CARs contain only the tyrosine-based fsignal-transducing subunit from the TCR/CD3 receptor complex 7-9 (Fig. 1a) , whereas second-generation CARs carry an additional costimulatory molecule such as CD28, CD27, DAP-12, 10 4-1BB (CD137), OX40 (CD134) 11 or inducible T cell costimulator (ICOS) 12 adjacent to the f domain (Fig. 1b) . In fact, second-generation CARs mediated superior activation, proliferation and in vivo persistence to T cells compared to first-generation CARs. 13 Third-generation CARs, in turn, include two costimulatory molecules within their CAR constructs [14] [15] [16] and have shown enhanced CAR T cell activation in vitro and in vivo, sustained proliferation and tumor-lytic activity as well as reduced activation-induced cell death [17] [18] [19] ( Fig. 1c) . Clinical trials to date have almost all relied on second-or third-generation CAR constructs, although it remains to be elucidated whether third-generation CARs display advantages in the clinical setting over second-generations CARs. 20 They might be associated with a better or worse safety profile. Concerns are that the synergistic effect of the triple signaling domains might reduce the activation threshold of third-generation CARs to a level where the activation of a CAR T cell would occur without the encounter of antigen.
CAR T Cells in CD19-Positive Hematologic
Malignancies: A Story of Success CAR T cell therapy for CD19-positive hematologic malignancies such as ALL, chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL) in a relapsed or refractory setting has generated promising results: clinical responses in up to 81% of ALL, 50% of CLL and 40% of NHL heavily pretreated patients have been reported for adult and pediatric leukemia and lymphoma patients. 21 Although CD19 does not represent a classical tumor-associated antigen (TAA), success of CD19-targeted CAR T cell therapy correlates directly with the nature of CD19: CD19 represents an ideal target given that it is exclusively expressed on B cells during all stages of their differentiation, maintained on over 95% of B cells that have undergone neoplastic transformation and is not expressed on other tissue. [22] [23] [24] Hypoglobulinemia mediated by anti-CD19 CAR B cell aplasia and used as a marker for CAR T cell persistence can be effectively treated via intravenous immunoglobulin replacement. 5, 25, 26 However, despite successful anti-tumor efficacy, CAR T cell therapy has shown to be associated with adverse effects including cytokine release syndrome (CRS), 27,28 on-tumor-off-target toxicity 29, 30 and neurotoxicity. 31 Whereas CRS is due to direct CAR T cell activity generating increased levels of cytokines and offtarget toxicity relies on the fact that a targeted TAA is exclusively expressed not only on malignant cells but also on healthy tissue, underlying mechanism of CAR T cell neurotoxicity remains unclear though also here, inflammatory cytokines seem to be involved. 32 Clinical management of CRS and neurotoxicity relies on application of steroids and the humanized monoclonal anti-IL-6 receptor antibody tocilizumab. 33 CAR T cell toxicity has ranged from manageable sideeffects in a majority of cases to severe toxicity including patient's deaths. 34, 35 Recently, fatal cerebral edema in five adult ALL patients led to the halt of a phase II clinical anti-CD19 CAR T cell trial (NCT 02535364). 36,37 It needs to be elucidated to which extent culture conditions, T cell stimulation, vector design and preconditioning regimens contribute to potential toxicity of CAR T cell therapy. Nonetheless, results of anti-CD19 CAR trials overcoming limitations of conventional therapy particularly in relapsed and refractory Neoantigens are highly immunogenic and derive from somatic mutations in tumors, hence representing ideal tumor-specific targets. Besides being suitable tools for personalized CAR design, generally applicable neoantigens are highly desirable. For example, epidermal growth factor variant III (EGFRvIII), a mutated EGF receptor expressed exclusively in malignant brain tissue that correlates with tumor invasion, angiogenesis and reduced patient's survival, has demonstrated safety in nine patients with glioblastoma multiforme treated with anti-EGFRvIII CAR T cells. 45 With regards to TSA, mesothelin, a surface glycoprotein, has gained much attention as CAR target given its high expression on a broad tumor range, i.e. metastatic mesothelioma, pancreatic or ovarian cancer. It is not a tumor-specific antigen since it is also expressed on normal tissue, although on low levels.
46,47 Mesothelin-directed CAR T cell therapy showed no events of off-tumor toxicity in clinical trials, but led to the formation of anti-CAR IgE antibodies leading to anaphylaxis 48 immunoglobulin kappa light chain (Igj) for CLL 61 and CD138 62 as well as B cell maturation antigen (BMCA) in multiple myeloma. 63, 64 However, a majority of neoantigens is intracellularly processed and presented by HLA class II molecules. Given that HLA-mediated presented antigens are invisible and inaccessible for CARs, TCR-mimic (TCRm) CARs directing the scFv domain against a peptide-HLA complex have further extended potential CAR target repertoire. For example, Wilms tumor 1 (WT1) peptide, an oncogenic zinc finger transcription factor overexpressed in AML as well as chronic myeloid leukemia (CML) and in solid tumors including mesothelioma, ovarian cancer glioblastoma or cancers of the GI tract, is presented in the context of HLA-A*02:01. 65, 66 Recently, an anti-WT1/HLA-A*02:01 directed TCRm CAR as the first CAR against a human intracellular protein has demonstrated efficacy in vivo in an AML mouse model. 67 In contrast to physiological TCRs and T cells, TCRm CARs are not selected in the thymus and lymphoid, therefore rising concerns in terms of the risk of autoimmune reactions. Potential off-tumor toxicity has to be investigated in depth before clinical TCRm CAR application.
Overcoming Barriers of Solid Tumors
In contrast to hematologic malignancies where CAR T cells encounter circulating target cells, CAR T cells in solid malignancies have to migrate and infiltrate tumor sites. Solid tumors, however, hinder CAR T cell migration and provide a hostile microenvironment characterized by physical and chemical obstacles: downregulation of adhesion molecules limit T cell trafficking, 68, 69 tumor stroma and extracellular matrix as well as abnormal vessel structure inhibit T cell infiltration and immunosuppressive molecules including TGF-ß, IL-10 or PD-L1 as well as immunoregulators such as T regulatory (T reg ) cells compromise T cell function.
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A strategy to overcome trafficking and migration issues consists in local delivery of CAR T cells to solid tumors: in contrast to systemic intravenous application, CAR T cells administered via intra-pleural or intra-cerebral injection have demonstrated improved anti-tumor efficacy and CAR T cell persistence in murine in vivo models, e.g. in mesothelioma 47 and glioblastoma, 70 respectively. Also, CARs expressing chemokinereceptors such as CXCR2/CCR2b (receptor for CXCL1) to target mesothelioma 71, 72 and CCR4 (receptor for CCL17) to target lymphoma 73 have shown to improve CAR T cell migration. Moreover, fourth-generation CAR T cells or CAR T cells redirected for universal cytokine killing (TRUCKs) have been developed (Fig. 1d ). Due to additional genetic modifications, these advanced CAR T cells express molecules to enhance CAR T cell efficacy. Expression of additional costimulatory ligands or cytokines to recruit and activate other effectors of the immune system augments response toward malignant cells. 74, 75 In fact, adding genetic information of costimulatory ligands such as 4-1BB-L, 76 CD40-L 77, 78 or proinflammatory cytokines such as IL-15, IL-7, IL-21 79, 80 within CAR constructs has mediated superior anti-tumor killing. IL-12 expressed by fourth-generation CAR T cells has conferred resistance to CAR T cells from T reg suppression in vivo and has questioned the need to additionally use lymphodepleting chemotherapy prior to CAR T cell administration. 81 Alternatively, inclusion of a CAR-inducible IL-12 cytokine cassette under the transcriptional control of a nuclear factor of activated T cells (NFAT) promoter within a CAR construct has gained attention given that not only TAA-expressing cells but also tumor cells negative for the target antigen were effectively destroyed due to recruitment of additional immune cells 82, 83 (Fig. 3a) . However, caution is warranted for the use of IL-12 in engineered T cells given toxicity. 84 Hence, either a strict control of interleukin-release or the use of cytokines with safe toxicity profiles are needed for safe clinical application of fourth-generation CAR T cells. In addition, armored CAR T cells able to express degrading enzymes such as heparanase have been designed and conferred CAR T cells with improved tumor infiltration capacity. 85 Approaches of CAR T cells targeting anti-angiogenetic factors such as the vascular growth factor receptor 2 (VEGFR2) on stromal tumor cells have achieved clinical responses only in a minority of patients. Disappointing results observing partial remission only in one of 24-treated patients highlight the need for further research. 86 Targeting inhibitory cytokines such as TGF-ß represents an interesting approach to overcome inhibition of CARs in solid tumors. Besides of direct negative impact on T cell effector functions, TGF-ß also promotes the formation of tumor metastasis. 87 Consequently, a CAR T cell deficient for TGF-ß-receptor and consequently resistant to TGF-ß suppression has been developed and displayed enhanced efficacy in vivo. signaling CARs (Fig. 3b) where a T cell co-expresses two different CAR molecules 89 or as bi-specific CAR (Fig. 3c) where one CAR molecule comprises two distinct binding domains. 90 
Increasing CAR Safety
Combinatorial antigen-targeting is not only helpful limiting target-negative relapses but can also be a strategy to improve CAR specificity and prevent off-tumor toxicity in the absence of truly tumor-specific antigens. Dual-receptor-based CAR systems can consist of one CAR that provides the activation signal whereas the second receptor, referred to as chimeric costimulatory receptor (CCR), mediates the costimulatory signal (Fig. 3d ). Only binding of two different antigens can induce effective CAR T cell activation. 91, 92 Likewise, dissociated CAR molecules relying on two different protein subunits to conform a functional CAR have been designed (Fig. 3e) . The antigen-binding domain is expressed on one subunit (subunit 1), whereas the intracellular signaling domain comprised on a second protein (subunit 2). Both subunits contain a dimerization module responsive to a small molecule. When binding of the small molecule occurs to subunit 1, heterodimerization with subunit 2 mediates the assembly of the fully functioning CAR. The rapamycin analog AP 21967, for example, has shown to be a suitable heterodimerizing small molecule in vitro and in vivo, hence acting as "ON" switch to closely control the CAR function. 93 Alternatively, synthetic Notch receptors (synNotch) have been introduced into dualreceptor systems to generate safe and effective CAR T cells (Fig. 3f) . synNotchs are modular receptors consisting of an extracellular target-recognition domain, a transmembrane and an intracellular transcription domain. After binding of a target to the synNotch extracellular domain, the intracellular segment releases a transcription factor that translocates into the nucleus. Here, it mediates transcription and expression of the CAR which, in turn, activates the CAR T cell when binding to the second target. 94, 95 Another approach to limit off-tumor toxicity targets on CAR affinity. Based on the density of antigen expression on the surface of target cells, affinity of CARs toward the respective antigen can be modified and enable CAR T cells to discriminate between malignant (high density) and normal (low density) cells. 96 CAR T cells with low affinity for EGFR have demonstrated selectivity for cells overexpressing EGFR and were not activated by normal tissue expressing lower levels of EGFR. 97 Self-limited CAR T cells transduced either by nonintegrating vector systems including electroporation of RNA or viral vectors such as adenovirus (AV) or adeno-associated virus (AAV) offer a safety advantage over integrating vector systems. 98 In contrast to integrating vector systems, the transgene of non-integrating vectors is lost over time in dividing cells, hence limiting potential long-term toxicity. However, the need for repeated infusions carries the risk of immunogenic reactions. In fact, anaphylaxis due to IgE development following repeated infusions of anti-mesothelin CAR T cells comprising a murine scFv transduced via electroporation has been reported. 48, 99 In addition, transient CAR expression results in reduced therapeutic efficacy given that clinical response has shown to correlate with persistence as well as long-term survival of engineered T cells. 100 To permanently turn-off CAR function and deplete CAR T cells in case of severe toxicity, engineered T cells can comprise suicide genes such as the herpes simplex virus thymidine kinase (HSV-TK) 101 or the inducible human caspase-9 (iCasp9) signaling domain 102 (Fig. 3g) . Whereas HSV-TK activated upon the administration of ganciclovir has raised some concerns regarding immunogenicity due to its viral origin, 103 iCasp9 is a fully human protein with minimal immunogenic potential. ICasp9 is activated by the dimerizing small molecule AP1903 104 and has proven feasibility in an anti-CD19/anti-CD20 CAR T cell model. 105, 106 It is currently being clinically tested in an anti-GD2 CAR system for sarcoma and neuroblastoma patients (NCT01953900; NCT02107963). Alternatively, CAR T cells expressing antigens such as the truncated EGFR (tEGFR) that endows a binding site for cetuximab can be introduced into CAR constructs not only to enable selective killing of CAR T cells via antibody administration but also to serve as a selection marker in vitro and tracking marker in vivo for transduced CAR T cells. 6 A similar approach has been proposed for CD20 in combination with rituximab 107, 108 and the epitope RQR8 targeted either by rituximab or an anti-CD34 monoclonal antibody. 109 
Universal CAR T Cells
Almost all CAR T cells administered to patients to date are personalized cell products that require time-consuming manufacturing. In the majority of cases, CAR T cell production is based on autologous cells. The development of allogeneic universal CAR T cells would render the possibility of quick, inexpensive and practical CAR T cell therapy since T cells from one donor could be used to manufacture CAR T cells for numerous patients. Furthermore, approaches enabling to redirect CAR T cells against various TAAs could render extended versatility to CAR T cell therapy and reduce the risk of tumor escape. A highly interesting universal CAR system referred to as Uni-CAR (Fig. 3h) , uses a dualtargeting approach to enable diverse CAR utilization: the scFv of the CAR does not recognize a cell surface antigen but a short nonimmunogenic peptide motif. This peptide motif is part of a soluble targeting module redirected against a specific tumor antigen. CAR effector function is only exerted when the target module has encountered its corresponding antigen. Whereas the CAR backbone remains unvaried, the targeting module can be easily exchanged. Not only is this a highly versatile CAR system that can simultaneously address multiple targets and enable rapid adaptation of CAR T cell technology to tumor dynamics, i.e. tumor escape, but also can CAR T cell function be strictly controlled given that CAR T cells are only active when the target module is administered. 110 To minimize the risk of rejection of allogeneic universal CAR T cells due to recognition of HLA molecules on the CAR T cell surface by the host immune system or graft-versus-host disease (GvHD) due to interaction of donor CAR T cells with the host's immune system, expression of molecules such as HLA or TCRs should be minimized. Genome-editing via zinc-finger nucleases (ZFN), 111 transcription activator-like effector nucleases (TALEN) 112 or clustered regularly interspaced short palindromic repeats (CRISPR) 113 can help to prevent expression of those molecules on donor CAR T cells. In fact, two pediatric ALL patients have been treated recently with universal CAR T cells previously edited via TALEN for TCRs. Patients achieved remission and subsequently received allogeneic stem cell transplantation (alloSCT). 114 Furthermore, to avoid immunogenicity, fully humanized CARs are advisable in a universal CAR T cell setting.
Enhancing CAR Efficacy via Combination Therapy
There is strong rationale for combining CAR T cell therapy with different anti-cancer approaches to achieve synergistic effects, decrease the risk for tumor evasion and improve the likelihood of effective clinical outcome. For example, chemotherapy in association with CAR T cell treatment has turned out essential since lymphodepletion not only reduces resident cell populations and creates space for infused CAR T cell expansion but also eliminates immunosuppressive cells. [115] [116] [117] Also, radiotherapy in conjunction with CAR T cell therapy can potentiate immunotherapeutic effects given that radiation has shown to promote the expression of adhesion molecules and TAAs on malignant cells. 118 Combination with CKi is another approach with the potential to overcome inhibition of CAR T cells and enhance anti-tumor response. Immune checkpoints are critical for normal immune function to limit immune responses and maintain self-tolerance. Activated T cells as well as CAR-expressing T cells express CTLA-4 L or PD-L1 as brakes to prevent overactivation and reduce the risk of autoimmunity. However, not only physiologic antigen presenting cells (APC) express the corresponding ligands, i.e. PD-1 and CTLA4. In tumors, malignant cells as well as stromal cells have shown to upregulate PD-L1 and CTLA-4 and render negative signals to activated T cells, thereby preventing detection and promoting exhaustion of T cells and CAR T cells. 119, 120 Anti-CTLA-4 and anti-PD-1 antibodies, amongst others Ipilimumab, Nivolumab or Pembrolizumab, have demonstrated durable remissions as well as prolongation of survival in oncologic patients. Interestingly, although complete remission rates in patients treated with CKi range below 15%, long-term survival and persistent long-term disease stabilization has been observed even years after finishing CKi treatment, 121, 122 CKi treatment is now approved for several malignancies, including amongst others melanoma, nonsmall lung cancer and Hodgkin's lymphoma. [123] [124] [125] Remarkable clinical activity of CKis urges their combination with CAR T cells. However, CKis cannot distinguish between good and bad players of the immune system and desirable enhancement of CAR T cells might be counterweighted by proliferation of autoimmune reactive T cells. Hence, toxicity profile of combined CKi 126 and CAR T cell application 126, 127 will have to be carefully evaluated before clinical application. Nonetheless, CKis have been recently used after alloSCT without resulting in GvHD in most of the patients. 128 After achieving remission following CAR T cell treatment, a strong rational for consolidating alloSCT exists since combining CAR T cell therapy with alloSCT has demonstrated to reduce the risk of relapse. 39 Although recently the need for alloSCT has been questioned given that overall survival of patients who received alloSCT after CAR T cell therapy did not differ significantly from patients that did not, 129 alloSCT seems a highly advisable consolidating tool given that CAR T cells alone may destroy tumor cells without being able to target the underlying stem cells.
Conclusion
CAR T cell therapy represents an innovative and highly effective tool in modern hematology and oncology. So far, it has been rather confined to CD19-positive leukemia and lymphoma demonstrating results even in heavily pretreated patients.
Solid tumors constitute a challenge for CAR T cell therapy due to elaborated mechanisms of concealment and tumor escape. Innovative CAR design and sophisticated strategies are on the way to overcome challenges and moreover provide smart CAR T cells with controllable function over time and dosage (Fig. 3) .
Not only novel CAR T cell technologies beyond thirdgeneration CARs but also combinations with other therapeutic entities (Fig. 2) have the potential to broaden the application and to enhance the efficacy of CAR T cell therapy in cancer patients. Target antigen density governs the efficacy of anti-CD20-CD28-CD3 zeta chimeric antigen
